These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 24210808)

  • 1. ²¹³Bi-anti-EGFR radioimmunoconjugates and X-ray irradiation trigger different cell death pathways in squamous cell carcinoma cells.
    Pickhard A; Piontek G; Seidl C; Kopping S; Blechert B; Mißlbeck M; Brockhoff G; Bruchertseifer F; Morgenstern A; Essler M
    Nucl Med Biol; 2014 Jan; 41(1):68-76. PubMed ID: 24210808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of HNSCC cells by 90Y-labeled cetuximab strictly depends on the number of induced DNA double-strand breaks.
    Saker J; Kriegs M; Zenker M; Heldt JM; Eke I; Pietzsch HJ; Grénman R; Cordes N; Petersen C; Baumann M; Steinbach J; Dikomey E; Kasten-Pisula U
    J Nucl Med; 2013 Mar; 54(3):416-23. PubMed ID: 23345302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.
    Pfost B; Seidl C; Autenrieth M; Saur D; Bruchertseifer F; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
    J Nucl Med; 2009 Oct; 50(10):1700-8. PubMed ID: 19793735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD33-antibodies labelled with the alpha-emitter Bismuth-213 kill CD33-positive acute myeloid leukaemia cells specifically by activation of caspases and break radio- and chemoresistance by inhibition of the anti-apoptotic proteins X-linked inhibitor of apoptosis protein and B-cell lymphoma-extra large.
    Friesen C; Roscher M; Hormann I; Leib O; Marx S; Moreno J; Miltner E
    Eur J Cancer; 2013 Jul; 49(11):2542-54. PubMed ID: 23684782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α-Radioimmunotherapy with ²¹³Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma.
    Teiluf K; Seidl C; Blechert B; Gaertner FC; Gilbertz KP; Fernandez V; Bassermann F; Endell J; Boxhammer R; Leclair S; Vallon M; Aichler M; Feuchtinger A; Bruchertseifer F; Morgenstern A; Essler M
    Oncotarget; 2015 Mar; 6(7):4692-703. PubMed ID: 25576914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic properties of radionuclide-conjugated Cetuximab without and in combination with external irradiation in head and neck cancer cells in vitro.
    Eke I; Ingargiola M; Förster C; Kunz-Schughart LA; Baumann M; Runge R; Freudenberg R; Kotzerke J; Heldt JM; Pietzsch HJ; Steinbach J; Cordes N
    Int J Radiat Biol; 2014 Aug; 90(8):678-86. PubMed ID: 24597752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenation.
    Wulbrand C; Seidl C; Gaertner FC; Bruchertseifer F; Morgenstern A; Essler M; Senekowitsch-Schmidtke R
    PLoS One; 2013; 8(5):e64730. PubMed ID: 23724085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor.
    Modjtahedi H; Eccles S; Sandle J; Box G; Titley J; Dean C
    Cancer Res; 1994 Apr; 54(7):1695-701. PubMed ID: 8137284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioimmunotherapy with α-particle-emitting radionuclides.
    Seidl C
    Immunotherapy; 2014; 6(4):431-58. PubMed ID: 24815783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.
    Huang SM; Harari PM
    Clin Cancer Res; 2000 Jun; 6(6):2166-74. PubMed ID: 10873065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Locoregional alpha-radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody.
    Huber R; Seidl C; Schmid E; Seidenschwang S; Becker KF; Schuhmacher C; Apostolidis C; Nikula T; Kremmer E; Schwaiger M; Senekowitsch-Schmidtke R
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3922S-8S. PubMed ID: 14506190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential of a Cetuximab-based radioimmunotherapy combined with external irradiation manifests in a 3-D cell assay.
    Ingargiola M; Runge R; Heldt JM; Freudenberg R; Steinbach J; Cordes N; Baumann M; Kotzerke J; Brockhoff G; Kunz-Schughart LA
    Int J Cancer; 2014 Aug; 135(4):968-80. PubMed ID: 24615356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility of the human pathogenic fungi Cryptococcus neoformans and Histoplasma capsulatum to gamma-radiation versus radioimmunotherapy with alpha- and beta-emitting radioisotopes.
    Dadachova E; Howell RW; Bryan RA; Frenkel A; Nosanchuk JD; Casadevall A
    J Nucl Med; 2004 Feb; 45(2):313-20. PubMed ID: 14960655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ¹¹¹In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer.
    Fasih A; Fonge H; Cai Z; Leyton JV; Tikhomirov I; Done SJ; Reilly RM
    Breast Cancer Res Treat; 2012 Aug; 135(1):189-200. PubMed ID: 22736376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells.
    Friesen C; Glatting G; Koop B; Schwarz K; Morgenstern A; Apostolidis C; Debatin KM; Reske SN
    Cancer Res; 2007 Mar; 67(5):1950-8. PubMed ID: 17332322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
    Chinnaiyan P; Huang S; Vallabhaneni G; Armstrong E; Varambally S; Tomlins SA; Chinnaiyan AM; Harari PM
    Cancer Res; 2005 Apr; 65(8):3328-35. PubMed ID: 15833866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative biological effectiveness of high linear energy transfer α-particles for the induction of DNA-double-strand breaks, chromosome aberrations and reproductive cell death in SW-1573 lung tumour cells.
    Franken NA; Hovingh S; Ten Cate R; Krawczyk P; Stap J; Hoebe R; Aten J; Barendsen GW
    Oncol Rep; 2012 Mar; 27(3):769-74. PubMed ID: 22200791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines.
    Hoffmann T; Hafner D; Ballo H; Haas I; Bier H
    Anticancer Res; 1997; 17(6D):4419-25. PubMed ID: 9494544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the radiotoxicity of two alpha-particle-emitting immunoconjugates, terbium-149 and bismuth-213, directed against a tumor-specific, exon 9 deleted (d9) E-cadherin adhesion protein.
    Miederer M; Seidl C; Beyer GJ; Charlton DE; Vranjes-Duric S; Comor JJ; Huber R; Nikula T; Apostolidis C; Schuhmacher C; Becker KF; Senekowitsch-Schmidtke R
    Radiat Res; 2003 May; 159(5):612-20. PubMed ID: 12710872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.